Lawrence Lamb
Executive Vice President & Chief Scientific Officer IN8Bio
Dr. Lawrence Lamb leads scientific and translational strategy as scientific co-founder, Executive Vice President, and Chief Scientific Officer of IN8Bio. While originally extending his NP clinical training in cardiovascular disease as a PhD student, he switched gears and studied immunology, finishing his PhD with a concentration in inflammatory lung disease and macrophage biology followed by postdoctoral training in molecular evolution and genetic engineering of mouse embryonic stem cells to define gene function. During a second clinical and research postdoc in transplantation immunology at the South Carolina Cancer Center he was the first to describe the association between relapse-free survival and homeostatic gamma delta T cell recovery in high-risk leukemia patients. While continuing this work as an Associate Professor and later Professor of Medicine at the University of Alabama at Birmingham, Dr. Lamb developed the scientific support for chemotherapy resistant gamma delta T cell-based immunotherapy for high-grade brain tumors. This work eventually culminated in successful IND applications that lead to the formation of IN8Bio. Over the course of his career, Dr. Lamb’s work has been funded by a diverse array of government and charitable foundations including the NCI, NHLBI, NCRR, NINDS, the Children’s Oncology Group, the Elsa Pardee Foundation, the Leukemia and Lymphoma Society, and the National Brain Tumor Foundation including the Samuel Gerson Leadership Chair for Glioblastoma Research.
Seminars
Join this workshop to explore the diverging pathways of drug development when T-Cell Engagers are applied to either lifethreatening malignancies or chronic autoimmune conditions.
- Analyzing the dual-target potential of CD38 to achieve deep plasma cell depletion and debating how the shift from oncology-level remission to autoimmune level long-term safety alters the risk benefit profile for chronic conditions
- Exploring alternative non-clinical models to prioritize immune restoration over cell depletion and debating the validity of NHP studies for predicting long-term tolerance
- Benchmarking MABEL-based dosing strategies in nonterminal patients and assessing computational modelling as a tool to bridge the gap between oncology’s toxicity-driven and autoimmunity’s safety-driven thresholds
- Evaluating the translational evidence required to justify the risk of chronic exposure and addressing the predictive limitations of traditional oncology safety packages for autoimmune use
- Shifting from oncology’s maximum potency mindset to a safety-first model by optimizing immune thresholds for chronic B-cell or T-cell depletion
- Leveraging lessons from oncology to eliminate high-grade CRS and ICANS, ensuring a benign safety profile suitable for non-malignant, chronic indications
- Utilizing tissue-restricted targeting and refined dosing to achieve long-term immune reset while preserving overall patient safety
